Interleukin-1 receptor antagonist deficiency with a novel mutation; Late onset and successful treatment with canakinumab: A case report

Ezgi Ulusoy, Neslihan Edeer Karaca, Hatem El-Shanti, Erhan Kilicoglu, Guzide Aksu, Necil Kutukculer

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: Interleukin-1 receptor antagonist deficiency is a rare autoinflammatory disease involving neonatal onset of pustulosis, periostitis, and sterile osteomyelitis. The underlying genetic abnormality involves a recessive mutation in IL1RN, which encodes interleukin-1 receptor antagonist. In this case report, we describe a case of a 12-year-old Turkish girl who initially was presented at 1 year of age, older than previously reported children with interleukin-1 receptor antagonist deficiency, and with a novel mutation, p.R26X, in ILR1N. Case presentation: Our patient developed pustular cutaneous lesions at 1 year of age. At the age of 12 years, she was hospitalized for arthralgia of her knees, elbows, and ankles and arthritis of the left knee, with simultaneous pustular cutaneous lesions. She was admitted to the intensive care unit because of septicemia and respiratory insufficiency during follow-up. A skin biopsy of hyperpigmented lesions demonstrated neutrophil infiltration in the epidermis and subepidermal pustular dermatosis. Interleukin-1 receptor antagonist deficiency was suspected, and genetic analysis revealed a homozygous mutation (p.R26X) in IL1RN, which led to a diagnosis of interleukin-1 receptor antagonist deficiency. Treatment with canakinumab (recombinant human anti-human interleukin-1β monoclonal antibody) 150mg subcutaneously once every 6 weeks was initiated. Our patient did not experience further cutaneous lesions or arthritis. Her post-treatment inflammatory markers were normal; she gained weight; and she was able to walk independently. Conclusions: In this case report, we describe a patient with interleukin-1 receptor antagonist deficiency who responded excellently to canakinumab treatment. We believe more awareness is warranted for interleukin-1 receptor antagonist deficiency in children. It is possible that the mutation in our patient was a founder mutation that may lead to diagnosis of additional cases in Turkey.

Original languageEnglish
Article number145
JournalJournal of Medical Case Reports
Volume9
Issue number1
DOIs
Publication statusPublished - 23 Jun 2015

    Fingerprint

Keywords

  • Autoinflammation
  • Canakinumab
  • Interleukin-1 receptor antagonist deficiency

ASJC Scopus subject areas

  • Medicine(all)

Cite this